Holen Sie sich die Stockscreener-App
5.925
14.16%
0.735
Vorhandelsmarkt:
5.89
-0.035
-0.59%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$5.19
Offen:
$5.38
24-Stunden-Volumen:
1.25M
Relative Volume:
1.10
Marktkapitalisierung:
$461.62M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-1.949
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
+10.54%
1M Leistung:
+34.51%
6M Leistung:
+54.30%
1J Leistung:
+14.38%
1-Tages-Spanne:
$5.355
$5.97
1-Wochen-Bereich:
$4.92
$5.97
52-Wochen-Spanne:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Vergleichen Sie SLDB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.925 | 404.35M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Eingeleitet | Needham | Buy |
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences CEO Cumbo sells $55k in shares - Investing.com
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst - Benzinga
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Solid Biosciences (SLDB) Receives Buy Rating Amid Competitive Ad - GuruFocus
SLDB Receives "Buy" Rating from Needham with $16 Target Price | SLDB Stock News - GuruFocus
How Solid Biosciences Inc. stock performs in rising dollar environment2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences (Nasdaq: SLDB) issues 23,284 RSUs under 2024 inducement plan - Stock Titan
Solid Biosciences' SGT-212 Receives Rare Pediatric Disease Designation to Treat Friedreich's Ataxia - MarketScreener
Solid Biosciences (SLDB) Gains Key FDA Designation for Gene Ther - GuruFocus
Solid Biosciences Receives FDA Rare Pediatric Disease and Fast Track Designations for SGT-212, a Novel Gene Therapy for Friedreich’s Ataxia - Quiver Quantitative
Solid Biosciences Inc. Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia - marketscreener.com
Franklin Resources Inc. Has $7.79 Million Position in Solid Biosciences Inc. $SLDB - MarketBeat
Is Solid Biosciences Inc. stock a bargain at current levels2025 Volatility Report & AI Enhanced Trading Alerts - moha.gov.vn
UBS Reaffirms Their Buy Rating on Credit Agricole (0HAI) - The Globe and Mail
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia - MSN
Solid Biosciences (SLDB) Stock Analysis Report | Financials & Insights - Benzinga
Can Kennametal India Limited Deliver Relative Outperformance to SectorDebt-to-Equity Ratio Analysis & Access Free Tools and Start Investing - earlytimes.in
Is Solid Biosciences Inc a good long term investmentTake Profit Strategies & Free Discover Dynamic Stocks - earlytimes.in
Using Bollinger Bands to evaluate Solid Biosciences Inc.July 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Why Solid Biosciences Inc. stock is trending among retail tradersJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
How to forecast Solid Biosciences Inc. trends using time seriesGap Up & Weekly Market Pulse Updates - newser.com
What insider trading reveals about Solid Biosciences Inc. stockJuly 2025 Trends & Intraday High Probability Alerts - newser.com
Candlestick signals on Solid Biosciences Inc. stock todayMarket Sentiment Report & Long-Term Safe Investment Plans - newser.com
Strategies to average down on Solid Biosciences Inc.Watch List & Daily Stock Trend Watchlist - newser.com
What MACD signals say about Solid Biosciences Inc.July 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Is Solid Biosciences Inc. stock positioned for long term growth - newser.com
Solid Biosciences licenses next-generation AAV capsid to Andelyn By Investing.com - Investing.com Nigeria
Solid Biosciences stock rises after licensing next-generation capsid By Investing.com - Investing.com Nigeria
Solid Biosciences stock rises after licensing next-generation capsid - Investing.com
Solid Biosciences Grants Capsid AAV-SLB101 License to Andelyn Biosciences - MarketScreener
Andelyn Biosciences Signs Licensing Agreement with Solid Biosciences - Contract Pharma
Solid Biosciences (SLDB) Partners with Andelyn Biosciences for G - GuruFocus
Solid Biosciences licenses next-generation AAV capsid to Andelyn - Investing.com
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 - The Manila Times
Solid Biosciences Licenses Next-Generation Capsid AAV-SLB101 to Andelyn Biosciences for Gene Therapy Development - Quiver Quantitative
Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences For The Use Of Proprietary Next-Generation Capsid Aav-Slb101 - TradingView
What’s next for Solid Biosciences Inc. stock priceMarket Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
How sustainable is Solid Biosciences Inc. stock dividend payoutPortfolio Performance Report & Daily Volume Surge Signals - newser.com
What momentum indicators show for Solid Biosciences Inc. stockJuly 2025 Closing Moves & Reliable Volume Spike Trade Alerts - newser.com
Applying sector rotation models to Solid Biosciences Inc.CPI Data & Accurate Technical Buy Alerts - newser.com
Does Solid Biosciences Inc. stock trade at a discount to peers2025 Short Interest & Reliable Momentum Entry Alerts - newser.com
How to monitor Solid Biosciences Inc. with trend dashboards2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Solid Biosciences director Ganot sells $13,505 in stock By Investing.com - Investing.com India
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Solid Biosciences Inc-Aktie (SLDB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cumbo Alexander | President and CEO |
Dec 03 '25 |
Sale |
5.11 |
10,808 |
55,229 |
81,388 |
| Hanrahan Jessie | Chief Regulatory Officer |
Dec 03 '25 |
Sale |
5.11 |
4,483 |
22,908 |
26,660 |
| Herzich Paul | Chief Technology Officer |
Dec 03 '25 |
Sale |
5.11 |
2,701 |
13,802 |
26,622 |
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):